Tuesday

17th Oct 2017

Column / Health Matters

Is Brexit a risk to our health?

  • People seem more worried in the Brexit debate about the relocation of the European Medicines Agency building, than the more important issue of risks to European public health. (Photo: Rob Bye)

The most prominent concern raised in the Brexit debate on healthcare, so far, has been the relocation of the European Medicines Agency (EMA) from London to another keen host city.

This issue is relatively trivial, given that the UK and EU faces a greater problem - critical health products could be stuck at the borders in under two years, when the Article 50 timeline ends.

Thank you for reading EUobserver!

Subscribe now for a 30 day free trial.

  1. €150 per year
  2. or €15 per month
  3. Cancel anytime

EUobserver is an independent, not-for-profit news organization that publishes daily news reports, analysis, and investigations from Brussels and the EU member states. We are an indispensable news source for anyone who wants to know what is going on in the EU.

We are mainly funded by advertising and subscription revenues. As advertising revenues are falling fast, we depend on subscription revenues to support our journalism.

For group, corporate or student subscriptions, please contact us. See also our full Terms of Use.

If you already have an account click here to login.

  • If products developed and manufactured in the UK cannot be freely sold to the EU single market, inward investment by non-EU countries may be at risk. (Photo: PressReleaseFinder)

There is a risk that health policy will be a neglected concern for policymakers on both sides, considering that Brussels has never held true competence to legislate on the area.

In October 2016, the then president of the European Parliament, Martin Schulz, asked parliamentary committees to sketch out the main challenges posed by Brexit to support the EU’s preparations for the negotiations.

The Committee on Environment, Public Health and Food Safety (Envi) responded in January of this year and raised apprehension regarding the EU’s primary responsibility in health – setting the process by which medicines and medical technologies are approved for sale on the single market.

Access to health products

Health is one of the most highly regulated sectors, because of the high potential impact on people’s health and well-being.

The EU legislation that enacts these systems is highly complex, actively applied (including, for example, regular in-person inspections) and changes regularly to try and find a balance between allowing patients access to exciting new treatments quickly, and ensuring that they are safe.

All aspects involved in the development of medicines – including clinical trials – must be conducted in line with specific EU legislation.

Manufacturers must prove the safety and efficacy of their medicine to the EMA before it can be sold.

Medical devices and diagnostics are approved for sale in the EU in a different manner towards the same end – by the awarding of CE marks by notified bodies under the watch of national governments and the European Commission. CE marks indicate indicate that the products conform with relevant EU directives regarding health and safety,

The UK’s departure from this system, especially as a prominent player in the life sciences sector, poses challenges, which was highlighted by the parliament’s Envi committee.

As neither a full EU member nor a member of the EU single market, the most likely future for the UK, as it looks today, will be based on a decision on whether to adopt its own sovereign system to ensure safety and efficacy of health products, or rather to write the current EU legislation into national law books.

The EU would likely only accept a mutual recognition of this kind if the UK commits to implementing all future changes to its national laws, too, but without the power that the country has today to influence those laws.

An agreement must be reached before the exit for the continued availability of products across both UK and EU territories, otherwise patients on both sides may not have access to products when they need them.

From the UK perspective, there are no persuasive arguments in favour of developing a new and different system of regulating health products, as it would complicate the situation for manufacturers who import and export products from the UK.

Frictionless borders

The UK has been a popular destination for inward investment from the US in the health sector. The EU’s economy and public health have benefited from this dynamic.

There is a tension now that threatens to impact the status quo on healthcare investment, especially in the UK.

There are two types of overseas investment. Firstly, infrastructure to make existing products available overseas (sales, marketing, business) and, secondly, infrastructure to develop and make new products (R&D and manufacturing).

Both types of investment are valuable, but the development of new and breakthrough products is especially prized. The value generated is considered to be higher, particularly due to its potential to create more high-level scientific and engineering jobs.

If products developed and manufactured in the UK cannot be freely sold to the EU single market, and without any trade agreements in place with the rest of the world, the UK risks its favourable position for inward investment by non-EU countries.

Company supply chains for delivering products to healthcare professionals and patients are as complex as the legislation, and based on the long-established status quo that a product manufactured in London yesterday can be packaged and sterilised in Berlin today and used on a patient in London again tomorrow.

This process heavily relies on frictionless borders.

While tariffs are not a major concern in health products given WTO humanitarian agreements, customs checks and paperwork caused by leaving the EU Customs Union would impact the ability to supply products in a timely fashion.

Given the acerbic early exchanges on Brexit, a scenario of restricted trade must not be discounted.

What about Ireland?

This also impacts Ireland, another favourite investment destination for US healthcare firms, considering that it would will be “cut off” from the rest of the EU geographically.

Today, transporting products by sea and by road through the UK to the EU from Ireland is commonplace.

In health, as in other sectors, there has been speculation about other business capitals vying to take business from Britain.

Some companies have already made symbolic announcements including Morgan Stanley. This is an overly simplistic view – the EU doesn’t just have to compete with the UK, it must vie with the world for investment.

While there is more business optimism around the eurozone economy than any time since 2008, it is not generally an exciting investment proposition for high returns.

A CEO of a healthcare company could be forgiven for thinking that redirecting investment from the UK to India is a more forward-thinking move than taking it to France. A CEO of a US company may be well advised to invest at home, given that they could be chided by president Donald Trump for not being seen to put “America First”.

Horizon 2020

Horizon 2020 research funding is closely related to the UK’s “divorce bill”. There is a total of €7.5 billion available for health research under the program.

The UK is considered a world leader in life sciences research, and one of the largest contributors to the EU budget. More Horizon 2020 projects are coordinated by UK-based scientists than any other country.

Horizon 2020 will end 20 months after Brexit, assuming that no extensions to the exit are agreed.

A failure to agree on the financial exit agreement, which the European Council and Commission insist must be done first, would mean that the UK would not fully finance Horizon 2020 until its conclusion. This is because member state contributions to the program are due to be made until the mid-2020s.

Subsequent disagreements about the ownership of valuable intellectual property derived from Horizon 2020 research could be foreseen, and may spell the end for the possibility of a partner arrangement for the UK in future.

FP9, the EU programme to follow Horizon at the end of 2020, will therefore see both EU and UK citizens lose out, given the knock to both the prestige of the current program and the total budget. This highlights the value of collective governmental funding of research, and the benefit of collaboration with peers.

The free movement of people within the EU has seen UK public health benefit by being able to attract high-level talent in academia, private research and filling crucial National Health Service (NHS) healthcare professional roles.

Statistics on net migration, however, suggest unease among those who are resident in the UK by EU citizenship, and roles in the NHS are going unfulfilled due to lack of qualified candidates.

The attraction and retention of skilled healthcare workers will be a critical factor to address in the UK government’s new system for immigration, whether it is “Australian points-based” or otherwise, when the country takes back control.

Tusk's warning

In the immediate aftermath of the UK referendum, EU council president Donald Tusk, asserted that Brexit would be bad for everybody: the UK, the EU, and for the wider world. He meant this both economically and politically.

As the clock continues to tick down to March 2019, the Brexit deadline, the issues to be resolved in health are many and complex, and likely to be overlooked in favour of more political or “big ticket” issues, such as financial services.

The sour tone of initial discussions suggests stormy seas ahead in the negotiations, but it must be remembered that health is a high-stakes game.

Special agreements with respect of health would be more politically justifiable where public health is at risk. This option should be explored to ensure that public health is not set back on both sides of the negotiating table.

Steve Bridges is an independent health policy adviser in Brussels. His Health Matters column takes a closer look at health-related policies, issues and trends in the EU.

Crowded race to win EU medicines agency

As cities line up to take over the European Medicines Agency some fear a kerfuffle that could destabilise the agency's work and slow down the pace of approving new medicines.

Column / Health Matters

The yin and yang of Chinese medicine

Can traditional Chinese medicine help the modern European patient? Malta thinks so, in a new agreement with China.

Column / Health Matters

Does the EU live up to its promises on life sciences?

Small businesses play a huge role in the EU economy, especially in life sciences, and this is oft-repeated in political speeches. But do the policies reflect the rhetoric?

Stakeholder

Silicones - enabling the next big leap in prosthetics and health

Prosthetics have been used for hundreds of years, but for much of that time saw little technological development. Today, it is possible to replace lost limbs with high-tech prosthetics made with silicone, that function seamlessly and provide a natural appearance.

Supported by

Stakeholders' Highlights

  1. International Partnership for Human RightsEU Should Seek Concrete Commitments From Azerbaijan at Human Rights Dialogue
  2. European Jewish CongressEJC Calls for New Austrian Government to Exclude Extremist Freedom Party
  3. CES - Silicones EuropeIn Healthcare, Silicones Are the Frontrunner. And That's a Good Thing!
  4. EU2017EEEuropean Space Week 2017 in Tallinn from November 3-9. Register Now!
  5. European Entrepreneurs CEA-PMEMobiliseSME Exchange Programme Open Doors for 400 Companies Across Europe
  6. CECEE-Privacy Regulation – Hands off M2M Communication!
  7. ILGA-EuropeHealth4LGBTI: Reducing Health Inequalities Experienced by LGBTI People
  8. EU2017EEEHealth: A Tool for More Equal Health
  9. Mission of China to the EUChina-EU Tourism a Key Driver for Job Creation and Enhanced Competitiveness
  10. CECENon-Harmonised Homologation of Mobile Machinery Costs € 90 Million per Year
  11. ILGA-EuropeMass Detention of Azeri LGBTI People - the LGBTI Community Urgently Needs Your Support
  12. European Free AllianceCatalans Have Won the Right to Have an Independent State

Latest News

  1. No sign of Brexit 'speed-up' after May-Juncker dinner
  2. Report: EU defence strategy 'outsourced' to arms industry
  3. EU privacy rules tilt to industry, NGO says
  4. Malta shocked after car bomb kills crusading journalist
  5. Spanish and Catalan leaders continue stand-off
  6. May pleads for more, as EU makes Brexit gesture
  7. EU circles the wagons around Iran deal
  8. 'Think of the patients!' cry would-be EU agency hosts

Stakeholders' Highlights

  1. ECR GroupBrexit: Delaying the Start of Negotiations Is Not a Solution
  2. EU2017EEPM Ratas in Poland: "We Enjoy the Fruits of European Cooperation Thanks to Solidarity"
  3. Mission of China to the EUChina and UK Discuss Deepening of Global Comprehensive Strategic Partnership
  4. European Healthy Lifestyle AllianceEHLA Joins Commissioners Navracsics, Andriukaitis and Hogan at EU Week of Sport
  5. Nordic Council of MinistersNordic Council Representative Office Opens in Brussels to Foster Better Cooperation
  6. UNICEFSocial Protection in the Contexts of Fragility & Forced Displacement
  7. CESIJoin CESI@Noon on October 18 and Debate On: 'European Defence Union: What Next?'
  8. Nordic Council of MinistersNordic Innovation House Opens in New York to Support Start-Ups
  9. ILGA EuropeInternational Attention Must Focus on LGBTI People in Azerbaijan After Police Raids
  10. European Jewish CongressStrong Results of Far Right AfD Party a Great Concern for Germans and European Jews
  11. EU2017EEEU Finance Ministers Agreed to Develop New Digital Taxation Rules
  12. Mission of China to the EUGermany Stands Ready to Deepen Cooperation With China